---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-039220"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:27:04.774569+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Processa Pharmaceuticals doses first patient in Phase 2 trial of NGC-Cap for metastatic breast cancer

## Summary
- First patient dosed in Phase 2 trial (NCT06568692) of NGC-Cap vs capecitabine in 60-90 advanced/metastatic breast cancer patients.
- Phase 2 trial satisfies diligence milestone under license agreement with Elion Oncology for PCS6422; Condition Precedent date corrected to Oct 6, 2024.
- Three clinical sites with IRB approval activated; plans for ~30 sites worldwide.
- Interim analysis results from Phase 2 trial expected mid-2025.

## SEC filing metadata
- accession: 0001493152-24-039220
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315224039220/0001493152-24-039220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315224039220/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-039220
- JSON: https://secwatch.observer/filing/0001493152-24-039220.json
- Plain text: https://secwatch.observer/filing/0001493152-24-039220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.